Mostrar el registro sencillo del ítem

dc.contributor.authorFerrer, Irene
dc.contributor.authorQuintanal-Villalonga, Alvaro 
dc.contributor.authorMolina-Pinelo, Sonia
dc.contributor.authorGarcia-Heredia, Jose Manuel
dc.contributor.authorPerez, Marco
dc.contributor.authorSuárez, Rocío
dc.contributor.authorPonce-Aix, Santiago
dc.contributor.authorPaz Ares , Luis Gonzaga 
dc.contributor.authorCarnero, Amancio
dc.date.accessioned2018-11-15T10:30:47Z
dc.date.available2018-11-15T10:30:47Z
dc.date.issued2018-08-17
dc.identifier.citationJ Exp Clin Cancer Res. 2018;es_ES
dc.identifier.issn1756-9966es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6597
dc.description.abstractBACKGROUND: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival. MAP17 (PDZK1IP1) is a small membrane-bound protein whose upregulation is reported as a common feature in tumours from diverse histological origins. Furthermore, MAP17 is correlated with tumour progression. METHODS: We assessed the expression of MAP17 in preclinical models, including cell lines and patient-derived xenografts (PDXs), assessing its correlation with sensitivity to different standard-of-care drugs in lung adenocarcinoma, as well as novel drugs. At the clinical level, we subsequently correlated MAP17 expression in human tumours with patient response to these therapies. RESULTS: We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors. In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas. CONCLUSIONS: Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy. Furthermore, we propose bortezomib treatment as a novel and efficacious therapy for lung adenocarcinomas exhibiting high MAP17 expression.es_ES
dc.description.sponsorshipThe authors thank the donors, the HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT13/0010/0056), and the Hospital 12 de Octubre Biobank for the human specimens used in this study.es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBiomarkerses_ES
dc.subjectLung canceres_ES
dc.subjectPDZK1IP1es_ES
dc.subjectTreatment efficacyes_ES
dc.subject.meshAdenocarcinoma es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshAged, 80 and over es_ES
dc.subject.meshBiomarkers, Tumor es_ES
dc.subject.meshBortezomib es_ES
dc.subject.meshCell Line, Tumor es_ES
dc.subject.meshCisplatin es_ES
dc.subject.meshFemale es_ES
dc.subject.meshGene Expression Regulation, Neoplastic es_ES
dc.subject.meshHumans es_ES
dc.subject.meshKaplan-Meier Estimate es_ES
dc.subject.meshLung Neoplasms es_ES
dc.subject.meshMale es_ES
dc.subject.meshMembrane Proteins es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshPrognosis es_ES
dc.subject.meshProteasome Inhibitors es_ES
dc.subject.meshProtein Kinase Inhibitors es_ES
dc.subject.meshReceptor, Epidermal Growth Factores_ES
dc.subject.meshXenograft Model Antitumor Assays es_ES
dc.titleMAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinomaes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID30119639es_ES
dc.format.volume37es_ES
dc.format.number1es_ES
dc.format.page195es_ES
dc.identifier.doi10.1186/s13046-018-0871-7es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderCentro de Investigación Biomedica en Red - CIBER
dc.contributor.funderAsociación Española Contra el Cáncer 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderRegional Government of Andalusia (España) 
dc.description.peerreviewed
dc.identifier.e-issn1756-9966es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s13046-018-0871-7.es_ES
dc.identifier.journalJournal of experimental & clinical cancer research : CRes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIOes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI15/00045es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CB16/12/00275es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CTS-1848es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI-0096-2014es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CD16/12/00442es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/R12/0036/0028es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI10/00033es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI-0046-2012es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI-0029-2013es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01311es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI1401964es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00778es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/DTS1700089es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PIE15/00076es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FI12/00429es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional